The Manufacturers Life Insurance Company raised its holdings in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 13.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,125 shares of the medical research company’s stock after purchasing an additional 2,425 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Accelerate Diagnostics were worth $578,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp boosted its holdings in Accelerate Diagnostics by 12.5% in the 2nd quarter. State Street Corp now owns 475,078 shares of the medical research company’s stock valued at $12,993,000 after purchasing an additional 52,817 shares during the period. Intrinsic Edge Capital Management LLC boosted its holdings in Accelerate Diagnostics by 181.1% in the 2nd quarter. Intrinsic Edge Capital Management LLC now owns 62,082 shares of the medical research company’s stock valued at $1,698,000 after purchasing an additional 40,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Accelerate Diagnostics by 265.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 74,013 shares of the medical research company’s stock valued at $2,024,000 after purchasing an additional 53,775 shares during the period. L & S Advisors Inc bought a new stake in Accelerate Diagnostics in the 2nd quarter valued at about $548,000. Finally, Stifel Financial Corp boosted its holdings in Accelerate Diagnostics by 123.2% in the 2nd quarter. Stifel Financial Corp now owns 25,552 shares of the medical research company’s stock valued at $693,000 after purchasing an additional 14,102 shares during the period. 45.43% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics, Inc. (NASDAQ AXDX) opened at $26.30 on Thursday. Accelerate Diagnostics, Inc. has a 12-month low of $16.75 and a 12-month high of $30.45.

COPYRIGHT VIOLATION NOTICE: “The Manufacturers Life Insurance Company Acquires 2,425 Shares of Accelerate Diagnostics, Inc. (AXDX)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/23/the-manufacturers-life-insurance-company-acquires-2425-shares-of-accelerate-diagnostics-inc-axdx.html.

AXDX has been the subject of several analyst reports. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, BidaskClub cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. Accelerate Diagnostics presently has a consensus rating of “Hold” and a consensus target price of $33.00.

In related news, Director Jack W. Schuler acquired 276,200 shares of the stock in a transaction that occurred on Thursday, October 12th. The stock was acquired at an average cost of $19.74 per share, for a total transaction of $5,452,188.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jack W. Schuler acquired 5,500 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were bought at an average price of $22.00 per share, with a total value of $121,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 981,667 shares of company stock valued at $18,879,924. 50.00% of the stock is owned by corporate insiders.

Accelerate Diagnostics Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.